The global pharmaceutical industry is emerging from a period of unprecedented change following restructuring and re-orientation of strategy, in response to a rapidly changing political, regulatory, fiscal and competitive environment.
Despite redefinition of functional architecture and strategy, we expect the industry to remain committed to the delivery of innovative new products as key drivers of sales, earnings and shareholder value. This will in turn ensure that the Life Science sector continues to offer significant opportunities for players that are sufficiently well managed, capitalised and commercially agile.
Akesios Associates provides financial strategy, representation and commercial development advice to Life Science companies.
We offer strategic and financial solutions that enhance corporate, and where appropriate, shareholder value. Akesios maintains an international capability, including emerging markets.
Our expertise draws on extensive capital markets, research and industry experience, incorporating product positioning, portfolio analysis, financial modelling, valuation, financing, M&A and investor communication.
We believe our clients should receive the highest levels of ethical support, independent of banking, trading or other conflicts of interest.